Quince Therapeutics Inc (NASDAQ: QNCX) is 2.86% higher on its value in year-to-date trading and has touched a low of $0.51 and a high of $1.43 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The QNCX stock was last observed hovering at around $1.19 in the last trading session, with the day’s loss setting it -0.11%.
Currently trading at $1.08, the stock is 33.15% and 43.93% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing -9.24% at the moment leaves the stock 16.08% off its SMA200. QNCX registered 11.33% gain for a year compared to 6-month loss of 1.89%. The firm has a 50-day simple moving average (SMA 50) of $0.7504 and a 200-day simple moving average (SMA200) of $0.930415.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 38.23% gain in the last 1 month and extending the period to 3 months gives it a 45.55%, and is 35.85% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 23.06% over the week and 11.96% over the month.
Quince Therapeutics Inc (QNCX) has around 32 employees, a market worth around $46.74M and $0.00M in sales. Distance from 52-week low is 111.10% and -24.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-86.72%).
.
Quince Therapeutics Inc (QNCX) Top Institutional Holders
54.0 institutions hold shares in Quince Therapeutics Inc (QNCX), with institutional investors hold 29.27% of the company’s shares. The shares outstanding are 42.97M, and float is at 32.08M with Short Float at 5.96%. Institutions hold 25.24% of the Float.
Quince Therapeutics Inc (QNCX) Insider Activity
The most recent transaction is an insider purchase by Thye Dirk, the company’s CEO AND CHIEF MEDICAL OFFICER. SEC filings show that Thye Dirk bought 77,000 shares of the company’s common stock on Aug 30 ’24 at a price of $0.70 per share for a total of $53900.0. Following the purchase, the insider now owns 0.84 million shares.
Quince Therapeutics Inc disclosed in a document filed with the SEC on Aug 29 ’24 that Thye Dirk (CEO AND CHIEF MEDICAL OFFICER) bought a total of 77,500 shares of the company’s common stock. The trade occurred on Aug 29 ’24 and was made at $0.69 per share for $53475.0. Following the transaction, the insider now directly holds 0.77 million shares of the QNCX stock.
Still, SEC filings show that on Aug 20 ’24, Ryan Charles S. (PRESIDENT) acquired 48,387 shares at an average price of $0.65 for $31452.0. The insider now directly holds 122,461 shares of Quince Therapeutics Inc (QNCX).
